Before We Slouch Into Turkey Day, Another High-Volume Week for IPOs

Also, send in your questions and join me Tuesday on <I>TSC's</I> message boards.
Publish date:

Here we are, staring down the barrel of another big week. There are 24 IPOs slated to price this week -- some pretty good, some garbage. Expect the calendar to slow down next week as we slide gracefully into the holiday of Thanks and Gluttony. My ramblings below will point you toward the deals that I like. Before you scroll down, I'd like to say a few things about my role here at

and the purpose of this weekly column.

First, I'm not a journalist assigned to write about IPOs. While journalism is an honorable profession, what I do is quite different. I spend 12 to 16 hours each day running a research shop, studying the IPO market and watching the deals trade. Most of the time it's fun. Sometimes it's a grind. On balance, though, I love what I do.

Q&A with Ben Holmes: Tuesday on


Message Boards.

Second, it is important that you understand that when I express an opinion about an IPO, that opinion is on the IPO, not on the stock days or weeks after the issue has hit the market. Buying IPOs at the issue price is a completely different ballgame than trading them in the aftermarket. The former is a fairly controlled market environment; the latter can be like walking barefoot through a medical waste landfill. Know the difference before you get involved.

As always, I welcome your questions. This week, I'm trying something new: a chat on


message boards.

Post your questions now on the boards and I'll answer them on Tuesday at 2 p.m. EST.

Meanwhile, trade safe and buy all of the hot ones the brokers will give you.

Let's look at the week ahead:

Ben Holmes is the founder of, a Boulder, Colo.-based research boutique specializing in the analysis of equity syndicate offerings. This column is not meant as investment advice; it is instead meant to provide insight into the methods of new and secondary offerings. Neither Holmes nor his firm has entered indications of interest in any of the companies discussed in this column. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Holmes appreciates your feedback at